Gallbladder Neoplasms: Clinical Trials

56 trials for Gallbladder Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

56 completed. 56 Phase 2, 6 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 256Completed 56
Phase 16Completed 6
Phase 33Completed 3

Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms

Trials (filtered) newest first · largest first

All 56 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer
Phase 1 / Phase 2CompletedArvinas Inc.762025-05-292026-11-17
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer
Phase 2CompletedLisata Therapeutics, Inc.662023-05-132026-09-28
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Phase 2CompletedInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest402022-05-232025-05-01
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.842022-04-132025-06-12
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib - Uterine Cervical Neoplasms, Endometrial Neoplasms
Phase 2CompletedMerck Sharp & Dohme LLC6112021-09-162026-09-28
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma
Phase 1 / Phase 2CompletedTransThera Sciences (Nanjing), Inc.2032021-03-142024-04-26
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
ZW25 (Zanidatamab) - HER2-amplified Biliary Tract Cancers
Phase 2CompletedJazz Pharmaceuticals872020-10-012025-09-15
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
Phase 1 / Phase 2CompletedIntima Bioscience, Inc.232020-05-152026-02-23
Pembrolizumab in Biliary Tract Cancer
Pembrolizumab, Cisplatin, Gemcitabine - Biliary Tract Cancer, Metastatic Cancer
Phase 2CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC502020-01-072023-11-03
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Irinotecan, Irinotecan Hydrochloride, Trifluridine and Tipiracil Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma
Phase 2CompletedMayo Clinic282019-10-182023-08-09
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
M7824 - Biliary Tract Cancer, Cholangiocarcinoma
Phase 2CompletedEMD Serono Research & Development Institute, Inc.1592019-03-262023-10-25
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma
Phase 2CompletedAIO-Studien-gGmbH1282018-05-022023-06-15
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)862018-02-082024-04-05
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
Varlitinib, Capecitabine - Biliary Tract Cancer
Phase 2CompletedASLAN Pharmaceuticals622017-12-192020-11-19
TAS-102 in Treating Advanced Biliary Tract Cancers
Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 - Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7
Phase 2CompletedMayo Clinic282017-10-202023-06-28
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer
Phase 2 / Phase 3CompletedASLAN Pharmaceuticals1512017-07-042021-08-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)112017-06-142021-12-03
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Cisplatin, Gemcitabine, Copanlisib - Biliary Carcinoma, Gall Bladder Carcinoma
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute242016-07-052021-08-04
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Ramucirumab - Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center612015-12-292023-06-15
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7
Phase 2CompletedM.D. Anderson Cancer Center622015-04-022022-02-02

Showing 20 of 56. Sign in to see all of them.

Narrower conditions

Bile Duct Neoplasms (26)  ·  Cholangiocarcinoma (24)  ·  Biliary Tract Neoplasms (14)  ·  Carcinoma, Hepatocellular (12)  ·  Liver Neoplasms (8)  ·  Pancreatic Neoplasms (7)  ·  Stomach Neoplasms (7)  ·  Neoplasm Metastasis (4)  ·  Neoplasms (4)  ·  Colonic Neoplasms (3)  ·  Esophageal Neoplasms (3)  ·  Klatskin Tumor (3)  ·  Thyroid Neoplasms (3)  ·  Triple Negative Breast Neoplasms (3)

Broader conditions

Biliary Tract Diseases (56)  ·  Digestive System Diseases (56)  ·  Neoplasms by Site (56)  ·  Digestive System Neoplasms (55)  ·  Gallbladder Diseases (55)  ·  Neoplasms (52)  ·  Biliary Tract Neoplasms (42)  ·  Neoplasms by Histologic Type (35)  ·  Neoplasms, Glandular and Epithelial (35)  ·  Adenocarcinoma (34)  ·  Carcinoma (33)  ·  Bile Duct Diseases (25)  ·  Liver Diseases (16)  ·  Endocrine Gland Neoplasms (10)  ·  Endocrine System Diseases (10)

Interventions

Gemcitabine (21)  ·  Capecitabine (14)  ·  Cisplatin (9)  ·  Oxaliplatin (8)  ·  Fluorouracil (5)  ·  Bevacizumab (4)  ·  Erlotinib Hydrochloride (4)  ·  Leucovorin (4)  ·  Sorafenib (3)  ·  durvalumab (3)  ·  pembrolizumab (3)  ·  130-nm albumin-bound paclitaxel (2)  ·  Albumin-Bound Paclitaxel (2)  ·  Carboplatin (2)  ·  Docetaxel (2)

Sponsors

National Cancer Institute (NCI) (11)  ·  Alliance for Clinical Trials in Oncology (3)  ·  M.D. Anderson Cancer Center (3)  ·  ASLAN Pharmaceuticals (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Mayo Clinic (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Roswell Park Cancer Institute (2)  ·  SWOG Cancer Research Network (2)  ·  TransThera Sciences (Nanjing), Inc. (2)  ·  Washington University School of Medicine (2)  ·  AIO-Studien-gGmbH (1)  ·  All India Institute of Medical Sciences (1)  ·  Arvinas Inc. (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)

Countries

United States (43)  ·  China (7)  ·  Spain (5)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  South Korea (4)  ·  Canada (3)  ·  Japan (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Chile (2)  ·  Poland (2)  ·  Australia (1)  ·  Colombia (1)

Top investigators

Steven R. Alberts, MD (3)  ·  Amit Mahipal (2)  ·  Anthony El-Khoueiry (2)  ·  Benjamin Tan, M.D. (2)  ·  Tanios Bekaii-Saab (2)  ·  Allyson Ocean (1)  ·  Anders Johnsson, MD, PhD (1)  ·  Aram Hezel, MD (1)  ·  Arndt Vogel, Prof. Dr. (1)  ·  Bruno Chauffert (1)  ·  Dieter Koeberle, MD (1)  ·  Edgar Ben-Josef, MD (1)  ·  Emil Lou, MD, PhD (1)  ·  Gao-jun Teng, MD, PhD (1)

Results publications

PMID 12794246, PMID 15558814, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19737952, PMID 20662793, PMID 20981545, PMID 21556747, PMID 25241229, PMID 25538178, PMID 25964250, PMID 30998813, PMID 32461347, PMID 33289918, PMID 34907910, PMID 35274717, PMID 36999533, PMID 37276871, PMID 37339254, PMID 38087967, PMID 39114870, PMID 40315882, PMID 40673842

NIH funding

U10CA032102 (4), 2023 (2), N01CM17104 (2), N01CM62201 (2), 2017 (1), 2018 (1), N01CM00070 (1), N01CM62204 (1), N01CM62207 (1), N01CM62209 (1), P30CA008748 (1), P30CA015083 (1), P30CA016058 (1), U01CA062505 (1), U10CA180888 (1)